197 related articles for article (PubMed ID: 21331814)
1. Low-dose paclitaxel enhances the anti-tumor efficacy of GM-CSF surface-modified whole-tumor-cell vaccine in mouse model of prostate cancer.
He Q; Li J; Yin W; Song Z; Zhang Z; Yi T; Tang J; Wu D; Lu Y; Wang Z; Liu D; Zhang X; Hu Z; Gao J
Cancer Immunol Immunother; 2011 May; 60(5):715-30. PubMed ID: 21331814
[TBL] [Abstract][Full Text] [Related]
2. A novel therapeutic vaccine of GM-CSF/TNFalpha surface-modified RM-1 cells against the orthotopic prostatic cancer.
Yin W; He Q; Hu Z; Chen Z; Qifeng M; Zhichun S; Zhihui Q; Xiaoxia N; Li J; Gao J
Vaccine; 2010 Jul; 28(31):4937-44. PubMed ID: 20653081
[TBL] [Abstract][Full Text] [Related]
3. PD-1/PD-L1 blockade enhances the efficacy of SA-GM-CSF surface-modified tumor vaccine in prostate cancer.
Shi X; Zhang X; Li J; Zhao H; Mo L; Shi X; Hu Z; Gao J; Tan W
Cancer Lett; 2017 Oct; 406():27-35. PubMed ID: 28797844
[TBL] [Abstract][Full Text] [Related]
4. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.
Nelson WG; Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Kim M; Weber CE; Baccala AA; Goeman MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF
Cancer Chemother Pharmacol; 2000; 46 Suppl():S67-72. PubMed ID: 10950151
[TBL] [Abstract][Full Text] [Related]
5. Depletion of regulatory T cells by anti-ICOS antibody enhances anti-tumor immunity of tumor cell vaccine in prostate cancer.
Mo L; Chen Q; Zhang X; Shi X; Wei L; Zheng D; Li H; Gao J; Li J; Hu Z
Vaccine; 2017 Oct; 35(43):5932-5938. PubMed ID: 28923424
[TBL] [Abstract][Full Text] [Related]
6. Harnessing T-cell activity against prostate cancer: A therapeutic microparticulate oral cancer vaccine.
Parenky AC; Akalkotkar A; Mulla NS; D'Souza MJ
Vaccine; 2019 Sep; 37(41):6085-6092. PubMed ID: 31477437
[TBL] [Abstract][Full Text] [Related]
7. Sequential administration of GM-CSF and IL-2 surface-modified MB49 cells vaccines against the metastatic bladder cancer.
Shi X; Zhang X; Li J; Guo F; Hu Z; Jing Y; Bai L; Chen S; Wan P; Wang F; Gao J; Tan W
Urol Oncol; 2013 Aug; 31(6):883-93. PubMed ID: 21924648
[TBL] [Abstract][Full Text] [Related]
8. The anti-tumor efficacy of a GM-CSF-secreting tumor cell vaccine is not inhibited by docetaxel administration.
Prell RA; Gearin L; Simmons A; Vanroey M; Jooss K
Cancer Immunol Immunother; 2006 Oct; 55(10):1285-93. PubMed ID: 16408214
[TBL] [Abstract][Full Text] [Related]
9. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
[TBL] [Abstract][Full Text] [Related]
10. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.
Machiels JP; Reilly RT; Emens LA; Ercolini AM; Lei RY; Weintraub D; Okoye FI; Jaffee EM
Cancer Res; 2001 May; 61(9):3689-97. PubMed ID: 11325840
[TBL] [Abstract][Full Text] [Related]
11. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
12. Cellular immunotherapy using irradiated lung cancer cell vaccine co-expressing GM-CSF and IL-18 can induce significant antitumor effects.
Tian H; Shi G; Yang G; Zhang J; Li Y; Du T; Wang J; Xu F; Cheng L; Zhang X; Dai L; Chen X; Zhang S; Yang Y; Yu D; Wei Y; Deng H
BMC Cancer; 2014 Jan; 14():48. PubMed ID: 24475975
[TBL] [Abstract][Full Text] [Related]
13. Induction of T-cell apoptosis in rats by genetically engineered glioma cells expressing granulocyte-macrophage colony-stimulating factor and B7.1.
Tseng SH; Chen Y; Chang CJ; Tai KF; Lin SM; Hwang LH
Clin Cancer Res; 2005 Feb; 11(4):1639-49. PubMed ID: 15746069
[TBL] [Abstract][Full Text] [Related]
14. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.
Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Lim M; Weber CE; Baccala AA; Goemann MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF; Nelson WG
Cancer Res; 1999 Oct; 59(20):5160-8. PubMed ID: 10537292
[TBL] [Abstract][Full Text] [Related]
15. A novel therapeutic vaccine of mouse GM-CSF surface modified MB49 cells against metastatic bladder cancer.
Zhang X; Shi X; Li J; Hu Z; Zhou D; Gao J; Tan W
J Urol; 2012 Mar; 187(3):1071-9. PubMed ID: 22266013
[TBL] [Abstract][Full Text] [Related]
16. PD-1 blockade enhances the antitumor efficacy of GM-CSF surface-modified bladder cancer stem cells vaccine.
Shi X; Zhang X; Li J; Mo L; Zhao H; Zhu Y; Hu Z; Gao J; Tan W
Int J Cancer; 2018 May; 142(10):2106-2117. PubMed ID: 29243219
[TBL] [Abstract][Full Text] [Related]
17. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
18. Benefits of gene transduction of granulocyte macrophage colony-stimulating factor in cancer vaccine using genetically modified dendritic cells.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Katsuda M; Miyazawa M; Yamaue H
Int J Oncol; 2007 Oct; 31(4):931-9. PubMed ID: 17786327
[TBL] [Abstract][Full Text] [Related]
19. Irradiated tumor cells adenovirally engineered to secrete granulocyte/macrophage-colony-stimulating factor establish antitumor immunity and eliminate pre-existing tumors in syngeneic mice.
Nagai E; Ogawa T; Kielian T; Ikubo A; Suzuki T
Cancer Immunol Immunother; 1998 Oct; 47(2):72-80. PubMed ID: 9769115
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice.
Pfannenstiel LW; Lam SS; Emens LA; Jaffee EM; Armstrong TD
Cell Immunol; 2010; 263(1):79-87. PubMed ID: 20346445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]